BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Given Consensus Rating of “Moderate Buy” by Brokerages

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) has been assigned an average rating of “Moderate Buy” from the twelve research firms that are currently covering the company, MarketBeat Ratings reports. Four research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. The average 12-month price target among brokers that have covered the stock in the last year is $20.80.

A number of analysts have recently commented on BCRX shares. Citizens Jmp upped their price target on BioCryst Pharmaceuticals from $25.00 to $28.00 and gave the company a “market outperform” rating in a research note on Thursday, May 7th. Wedbush reduced their price objective on shares of BioCryst Pharmaceuticals from $22.00 to $21.00 and set an “outperform” rating on the stock in a research note on Thursday, May 7th. JPMorgan Chase & Co. assumed coverage on shares of BioCryst Pharmaceuticals in a report on Monday, July 13th. They set a “neutral” rating and a $12.00 price objective for the company. Cantor Fitzgerald upped their target price on shares of BioCryst Pharmaceuticals from $27.00 to $29.00 and gave the company an “overweight” rating in a research note on Tuesday, June 30th. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of BioCryst Pharmaceuticals in a research note on Monday, June 1st.

BioCryst Pharmaceuticals Price Performance

BCRX opened at $9.34 on Monday. The firm has a 50 day simple moving average of $9.22 and a 200 day simple moving average of $8.58. BioCryst Pharmaceuticals has a fifty-two week low of $6.00 and a fifty-two week high of $11.22. The company has a market cap of $2.37 billion, a price-to-earnings ratio of -5.25 and a beta of 0.55.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported ($2.98) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.06 by ($3.04). BioCryst Pharmaceuticals had a negative net margin of 51.71% and a negative return on equity of 76.36%. The business had revenue of $156.41 million during the quarter, compared to the consensus estimate of $151.12 million. During the same period in the previous year, the business posted $0.20 earnings per share. BioCryst Pharmaceuticals’s revenue was up 7.5% compared to the same quarter last year. As a group, analysts expect that BioCryst Pharmaceuticals will post -2.58 EPS for the current year.

Institutional Trading of BioCryst Pharmaceuticals

Large investors have recently made changes to their positions in the company. Phocas Financial Corp. bought a new position in BioCryst Pharmaceuticals during the fourth quarter worth about $1,956,000. Aberdeen Group plc acquired a new stake in shares of BioCryst Pharmaceuticals during the fourth quarter worth $7,126,000. Vanguard Group Inc. boosted its stake in BioCryst Pharmaceuticals by 2.2% in the 4th quarter. Vanguard Group Inc. now owns 22,273,375 shares of the biotechnology company’s stock worth $173,732,000 after purchasing an additional 482,494 shares during the period. BNP Paribas Financial Markets raised its stake in shares of BioCryst Pharmaceuticals by 21.4% in the 4th quarter. BNP Paribas Financial Markets now owns 2,542,714 shares of the biotechnology company’s stock valued at $19,833,000 after purchasing an additional 448,436 shares during the period. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al raised its stake in shares of BioCryst Pharmaceuticals by 106.5% in the 4th quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 233,354 shares of the biotechnology company’s stock valued at $1,820,000 after purchasing an additional 120,350 shares during the period. Institutional investors own 85.88% of the company’s stock.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.